Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 6/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 4/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.36 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887915 | 0.88 | CNR2 (0.46) | — | |
| SCHEMBL6026686 | 0.84 | PTPN1 (0.48) | JAK1 | |
| SCHEMBL6027187 | 0.84 | PTPN1 (0.48) | JAK1 | |
| SCHEMBL6026524 | 0.82 | EPHX2 (0.47) | — | |
| SCHEMBL6026920 | 0.82 | EPHX2 (0.47) | — | |
| SCHEMBL6027331 | 0.82 | GSK3B (0.39) | — | |
| SCHEMBL6026827 | 0.81 | RAB9A (0.47) | NQO2 | |
| SCHEMBL6027147 | 0.81 | SCN3A (0.39) | JAK2JAK1JAK3NQO2 | |
| SCHEMBL6027254 | 0.78 | ALDH1A1 (0.47) | — | |
| SCHEMBL27636642 | 0.77 | NQO2 (0.36) | SCN2ANPY5RHPGDSHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1826111-A | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | AVANIR PHARMACEUTICALS (US) | 2006-08-30 | — | — | CN | disclosed |
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | AVANIR PHARMACEUTICALS | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | ICOS, TSLP, IKZF3 | SCN2A 4668/4885NPY5R 4342/4885TRPV1 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.